News Headlines

  1. Lilly Plans To Build A New €2.6B Facility To Boost Oral Medicine Manufacturing Capacity In Europe For Patients Worldwide 11/5/2025

    Eli Lilly and Company (NYSE: LLY) announced today plans to build a new €2.6 billion (3 billion USD) manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.

  2. XtalPi Subsidiary Ailux Announces Strategic Collaboration With Lilly To Advance Bispecific Antibody Development 11/5/2025

    Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and development of bispecific antibodies for the treatment of various diseases.

  3. Sandoz Boosts In-House Biosimilars Capabilities By Signing Agreement To Acquire Just-Evotec Biologics EU SAS In Toulouse 11/4/2025

    Sandoz, the global leader in affordable medicines, today announced a strategic agreement with Evotec SE to acquire all issued and outstanding equity interests of Just-Evotec Biologics EU SAS (JEB SAS) which includes the Toulouse manufacturing site.

  4. Merck Signs Agreement With Dr. Falk Pharma GmbH For Certain Development And Commercialization Rights To MK-8690 (PRA-052) An Investigational Anti-CD30 Ligand Monoclonal Antibody 11/4/2025

    Merck, known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerly PRA-052), and for Merck to assume full responsibility for the development program going forward.

  5. Merck Enters Into Research And Development Funding Agreement With Blackstone Life Sciences For Sacituzumab Tirumotecan (sac-TMT) 11/4/2025

    Merck, known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells.

  6. Ginkgo Bioworks Awarded Project Agreement Through BARDA's BioMaP-Consortium 11/3/2025

    Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to protect against and treat infection by filoviruses such as Ebola (EBOV) and Sudan Viruses (SUDV).

  7. Matica Bio, A CDMO Leader In Oncolytic Virus Manufacturing, Partners With Calidi Biotherapeutics To Advance Calidi's Project Toward IND 11/3/2025

    Matica Biotechnology, Inc. ("Matica Bio"), a leading viral vector CDMO specializing in advanced therapies, today announced a strategic partnership with Calidi Biotherapeutics, Inc. ("Calidi"), a clinical-stage immuno-oncology company developing next-generation oncolytic virus-based therapies.

  8. Samsung Biologics Completes Spin-Off To Strengthen Its Focus As A Pure-Play CDMO 11/3/2025

    Samsung Biologics today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO).

  9. ScaleReady Announces A G-Rex® Grant Has Been Awarded To Sonoma Biotherapeutics 11/3/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex® Grant.

  10. Lilly Plans To Build A New $3B Facility To Boost Oral Medicine Manufacturing Capacity In Europe For Patients Worldwide 11/3/2025

    Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.